CGC
Price
$1.40
Change
-$0.09 (-6.04%)
Updated
Sep 3 closing price
Capitalization
435.69M
64 days until earnings call
EVO
Price
$3.44
Change
+$0.04 (+1.18%)
Updated
Sep 3 closing price
Capitalization
1.2B
62 days until earnings call
Interact to see
Advertisement

CGC vs EVO

Header iconCGC vs EVO Comparison
Open Charts CGC vs EVOBanner chart's image
Canopy Growth
Price$1.40
Change-$0.09 (-6.04%)
Volume$21.79M
Capitalization435.69M
Evotec SE
Price$3.44
Change+$0.04 (+1.18%)
Volume$88.3K
Capitalization1.2B
CGC vs EVO Comparison Chart in %
Loading...
CGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CGC vs. EVO commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGC is a StrongBuy and EVO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (CGC: $1.39 vs. EVO: $3.44)
Brand notoriety: CGC: Notable vs. EVO: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CGC: 100% vs. EVO: 128%
Market capitalization -- CGC: $435.69M vs. EVO: $1.2B
CGC [@Pharmaceuticals: Generic] is valued at $435.69M. EVO’s [@Pharmaceuticals: Generic] market capitalization is $1.2B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.55B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGC’s FA Score shows that 0 FA rating(s) are green whileEVO’s FA Score has 1 green FA rating(s).

  • CGC’s FA Score: 0 green, 5 red.
  • EVO’s FA Score: 1 green, 4 red.
According to our system of comparison, both CGC and EVO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGC’s TA Score shows that 6 TA indicator(s) are bullish while EVO’s TA Score has 4 bullish TA indicator(s).

  • CGC’s TA Score: 6 bullish, 4 bearish.
  • EVO’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, CGC is a better buy in the short-term than EVO.

Price Growth

CGC (@Pharmaceuticals: Generic) experienced а -7.95% price change this week, while EVO (@Pharmaceuticals: Generic) price change was -1.43% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.02%. For the same industry, the average monthly price growth was +9.86%, and the average quarterly price growth was +87.27%.

Reported Earning Dates

CGC is expected to report earnings on Nov 07, 2025.

EVO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.02% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EVO($1.21B) has a higher market cap than CGC($436M). EVO YTD gains are higher at: -17.308 vs. CGC (-49.270). EVO has higher annual earnings (EBITDA): -121.33M vs. CGC (-410.31M). EVO has more cash in the bank: 356M vs. CGC (144M). EVO has less debt than CGC: EVO (107M) vs CGC (328M). EVO has higher revenues than CGC: EVO (777M) vs CGC (275M).
CGCEVOCGC / EVO
Capitalization436M1.21B36%
EBITDA-410.31M-121.33M338%
Gain YTD-49.270-17.308285%
P/E RatioN/AN/A-
Revenue275M777M35%
Total Cash144M356M40%
Total Debt328M107M307%
FUNDAMENTALS RATINGS
CGC vs EVO: Fundamental Ratings
CGC
EVO
OUTLOOK RATING
1..100
1360
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
93
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9995
PRICE GROWTH RATING
1..100
4384
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CGC's Valuation (93) in the Agricultural Commodities Or Milling industry is in the same range as EVO (93) in the null industry. This means that CGC’s stock grew similarly to EVO’s over the last 12 months.

CGC's Profit vs Risk Rating (100) in the Agricultural Commodities Or Milling industry is in the same range as EVO (100) in the null industry. This means that CGC’s stock grew similarly to EVO’s over the last 12 months.

EVO's SMR Rating (95) in the null industry is in the same range as CGC (99) in the Agricultural Commodities Or Milling industry. This means that EVO’s stock grew similarly to CGC’s over the last 12 months.

CGC's Price Growth Rating (43) in the Agricultural Commodities Or Milling industry is somewhat better than the same rating for EVO (84) in the null industry. This means that CGC’s stock grew somewhat faster than EVO’s over the last 12 months.

EVO's P/E Growth Rating (2) in the null industry is significantly better than the same rating for CGC (100) in the Agricultural Commodities Or Milling industry. This means that EVO’s stock grew significantly faster than CGC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CGCEVO
RSI
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
73%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
74%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
73%
Advances
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 27 days ago
69%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
CGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DIAYX30.430.02
+0.07%
Diamond Hill Long-Short Y
SNWCX60.09N/A
N/A
Easterly Snow Small Cap Value C
NPNEX50.21N/A
N/A
Neuberger Berman Large Cap Value E
CEISX13.96N/A
N/A
Manning & Napier Callodine Equity Inc S
SMFAX33.63-0.04
-0.12%
American Beacon Stephens Mid-Cap Gr A